Our goal is to develop broad spectrum, small molecule antivirals with high barriers to resistance against multiple Priority Pathogens. We discovered a novel specific phosphoinositide (PI)-4,5-bisphosphate (PI(4,5)P2, or

Public Health Relevance

In summary, we seek to develop new classes of host-targeting antiviral therapeutics based on inhibition of Pl-4- and PIP5- kinases, and that are capable of treating multiple NIAID Emerging and Re-emerging Priority Pathogen viruses, when used alone or in combination with other available agents.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
1U19AI109662-01
Application #
8643870
Study Section
Special Emphasis Panel (ZAI1-LR-M (J1))
Project Start
2014-04-10
Project End
2019-03-31
Budget Start
2014-04-10
Budget End
2015-03-31
Support Year
1
Fiscal Year
2014
Total Cost
$1,425,487
Indirect Cost
$485,023
Name
Stanford University
Department
Type
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305
Cho, Nam-Joon; Lee, Choongho; Pang, Phillip S et al. (2015) Phosphatidylinositol 4,5-bisphosphate is an HCV NS5A ligand and mediates replication of the viral genome. Gastroenterology 148:616-25